Accent Microcell LimitedACCENTMICCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Sep 2025 1 quarters of data

₹688.00

MCap ₹1,650 Cr

Accent Microcell Limited — Stock analysis & AI research Accent Microcell Limited — Seasonality — best & worst months Accent Microcell Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Profit Growth Stocks 📋 Stocks With Strong Quarterly Results 📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks 📋 Quality Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹142 Cr

Sales · Sep 2025

₹24 Cr

Operating Profit · Sep 2025

17.2%

OPM % · Sep 2025

₹18 Cr

Net Profit · Sep 2025

—

EPS · Sep 2025

📝 Accent Microcell Limited — results explained

Quarter ended September 2025 (Q2 FY26)

Accent Microcell Limited reported revenue of ₹142 crore for the quarter ended September 2025 (Q2 FY26).

Net profit stood at ₹18 crore.

Operating profit stood at ₹24 crore — an operating margin (OPM) of 17.2%.

Valuation snapshot

At the current price of ₹688.00, ACCENTMIC has a market capitalisation of ₹1,650 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 55.47%, foreign institutional investors (FIIs) 0.58%, domestic institutional investors (DIIs) 3.59%, public shareholders 40.36% of Accent Microcell Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹1,650 Cr

Current Price ?

₹688.0

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

5.43

P/S ?

N/A

P/FCF ?

-24.27

Enterprise Value ?

₹1,651 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

25.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹142 Cr

PAT — latest qtr ?

₹18 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹1 Cr

Debt to Equity ?

0.00

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

55.47%

Change in promoter holding ?

0.38%

Pledged percentage ?

N/A

Market

Return 3 months ?

34.0%

Return 6 months ?

58.7%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2025	YoY %	QoQ %
Sales	142	—	—
Operating Profit	24	—	—
Other Income	—	—	—
Interest	0	—	—
Depreciation	—	—	—
Profit Before Tax	24	—	—
Net Profit	18	—	—
EPS	—	—	—
OPM %	17.2%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 5 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Sep 2026	% Chg
Equity Capital	13	21	21	24	24	-0.0%
Reserves	37	143	174	252	280	+11.2%
Borrowings	23	13	2	1	1	-38.0%
Other Liabilities	37	28	32	45	41	-9.6%
Total Liabilities	111	205	228	322	346	+7.3%
Fixed Assets	31	29	48	53	56	+5.9%
CWIP	0	2	13	102	135	+32.0%
Investments	0	0	0	0	—	—
Other Assets	79	174	168	167	155	-7.4%
Total Assets	111	205	228	322	346	+7.3%

📦 Working Capital (latest 1 periods)

Metric	Sep 2026	% Chg
Inventories	35	—
Trade Receivables	45	—
Trade Payables	23	—

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	8	11	25	19	-24.0%
Cash from Investing Activity	-4	-82	-9	-49	-444.4%
Cash from Financing Activity	-4	72	-14	36	+357.1%
Net Cash Flow	-1	1	2	6	+200.0%
Free Cash Flow	3	-2	-12	-68	-466.7%
CFO/OP	53%	44%	85%	56%	-34.1%

💧 Half-year Cash Flow (latest 1 periods)

Metric	Sep 2026	% Chg
Cash from Operating Activity	78	—
Cash from Investing Activity	-85	—
Cash from Financing Activity	-3	—
Net Cash Flow	-9	—

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	56	80	90	95	+5.6%
Inventory Days	128	83	76	55	-27.6%
Days Payable	106	48	42	33	-21.4%
Cash Conversion Cycle	79	114	124	117	-5.6%
Working Capital Days	41	79	101	95	-5.9%
ROCE %	27%	31%	24%	25%	+4.2%

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	55.09%	55.44%	55.44%	55.47%	+0.1%
FIIs	0.01%	0.00%	0.29%	0.58%	+100.0%
DIIs	2.88%	3.29%	3.57%	3.59%	+0.6%
Public	42.01%	41.27%	40.70%	40.36%	-0.8%
No. of Shareholders	2,982	3,061	3,076	3,054	-0.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	ACCENTMIC Accent Microcell	₹286.90	688	12.1	385	57	19.3%	14.8%	—	—	25.4%	72.2%

❓ Frequently asked questions

What was Accent Microcell Limited's revenue in Q2 FY26?